Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2 : Prognostic factors and treatment selection based on two large randomized clinical trials

Journal of Thoracic Oncology

Volumn 4, Issue 7, 2009, Pages 869-874

  Lilenbaum, Rogerio ^a   Villaflor, Victoria M ^b   Langer, Corey ^c   O'Byrne, Kenneth ^d   O'Brien, Mary ^e   Ross, Helen J ^f   Socinski, Mark ^g   Oldham, Fred B ^h   Sandilac, Larissa ^a   Singer, Jack W ^a   Bonomi, Philip ⁱ  

^a Mount Sinai Cancer Center   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d ST JAMES S HOSPITAL   (Ireland)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h Cell Therapeutics Inc   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Combination chemotherapy; Gemcitabine; NSCLC; Paclitaxel poliglumex; Performance status 2; Prognostic model; Single agent chemotherapy; STELLAR; Vinorelbine

Indexed keywords

ALBUMIN; CARBOPLATIN; GEMCITABINE; LACTATE DEHYDROGENASE; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; THORAX DISEASE; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 68549094542     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a9a020     Document Type: Article

References (10)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable on-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353. (Pubitemid 41095099)
2. Ettinger D, Johnson B. Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005;3(Suppl 1):S17-S21. (Pubitemid 44265389)
3. Langer CJ, O'Byrne KJ, Socinski MA, et al. Phase III trial comparing paclitaxel Poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. In press.
4. O'Brien MER, Socinski MA, Popovich AY, et al. Randomized Phase III Trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC). J Thorac Oncol. In press.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
6. Lilenbaum RC, Cashy J, Hensing T, et al. Prevalence of poor performance status in lung cancer patients: implications for research. J Thoracic Oncol 2008;3:125-129. (Pubitemid 351323185)
7. Lilenbaum RC, Chen CS, Chidiac T, et al. Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 2005;16:97-101. (Pubitemid 40124485)
8. Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23:175-183. (Pubitemid 41702636)
9. Obasaju CK, Conkling P, Richards D, et al. A randomized phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients (pts) with advanced (stage IIIB with pleural effusion or stage IV) non-small cell lung cancer (NSCLC). J Clinical Oncol 2007;25:18S, (Suppl; Abstract 7533).
10. Lilenbaum R, Herndon J, List M, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness. Proc Am Soc Clin Oncol 2002;21:1a, (Abstract #2).